Cargando…

Frontotemporal Dementias: A Review

Dementia is a clinical state characterized by loss of function in multiple cognitive domains. It is a costly disease in terms of both personal suffering and economic loss. Frontotemporal dementia (FTD) is the term now preferred over Picks disease to describe the spectrum of non-Alzheimers dementias...

Descripción completa

Detalles Bibliográficos
Autores principales: Weder, Natalie D, Aziz, Rehan, Wilkins, Kirsten, Tampi, Rajesh R
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1906781/
https://www.ncbi.nlm.nih.gov/pubmed/17565679
http://dx.doi.org/10.1186/1744-859X-6-15
_version_ 1782134025766305792
author Weder, Natalie D
Aziz, Rehan
Wilkins, Kirsten
Tampi, Rajesh R
author_facet Weder, Natalie D
Aziz, Rehan
Wilkins, Kirsten
Tampi, Rajesh R
author_sort Weder, Natalie D
collection PubMed
description Dementia is a clinical state characterized by loss of function in multiple cognitive domains. It is a costly disease in terms of both personal suffering and economic loss. Frontotemporal dementia (FTD) is the term now preferred over Picks disease to describe the spectrum of non-Alzheimers dementias characterized by focal atrophy of the frontal and anterior temporal regions of the brain. The prevalence of FTD is considerable, though specific figures vary among different studies. It occurs usually in an age range of 35–75 and it is more common in individuals with a positive family history of dementia. The risk factors associated with this disorder include head injury and family history of FTD. Although there is some controversy regarding the further syndromatic subdivision of the different types of FTD, the three major clinical presentations of FTD include: 1) a frontal or behavioral variant (FvFTD), 2) a temporal, aphasic variant, also called Semantic dementia (SD), and 3) a progressive aphasia (PA). These different variants differ in their clinical presentation, cognitive deficits, and affected brain regions. Patients with FTD should have a neuropsychiatric assessment, neuropsychological testing and neuroimaging studies to confirm and clarify the diagnosis. Treatment for this entity consists of behavioral and pharmacological approaches. Medications such as serotonin reuptake inhibitors, antipsychotics, mood stabilizer and other novel treatments have been used in FTD with different rates of success. Further research should be directed at understanding and developing new diagnostic and therapeutic modalities to improve the patients' prognosis and quality of life.
format Text
id pubmed-1906781
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-19067812007-07-04 Frontotemporal Dementias: A Review Weder, Natalie D Aziz, Rehan Wilkins, Kirsten Tampi, Rajesh R Ann Gen Psychiatry Review Dementia is a clinical state characterized by loss of function in multiple cognitive domains. It is a costly disease in terms of both personal suffering and economic loss. Frontotemporal dementia (FTD) is the term now preferred over Picks disease to describe the spectrum of non-Alzheimers dementias characterized by focal atrophy of the frontal and anterior temporal regions of the brain. The prevalence of FTD is considerable, though specific figures vary among different studies. It occurs usually in an age range of 35–75 and it is more common in individuals with a positive family history of dementia. The risk factors associated with this disorder include head injury and family history of FTD. Although there is some controversy regarding the further syndromatic subdivision of the different types of FTD, the three major clinical presentations of FTD include: 1) a frontal or behavioral variant (FvFTD), 2) a temporal, aphasic variant, also called Semantic dementia (SD), and 3) a progressive aphasia (PA). These different variants differ in their clinical presentation, cognitive deficits, and affected brain regions. Patients with FTD should have a neuropsychiatric assessment, neuropsychological testing and neuroimaging studies to confirm and clarify the diagnosis. Treatment for this entity consists of behavioral and pharmacological approaches. Medications such as serotonin reuptake inhibitors, antipsychotics, mood stabilizer and other novel treatments have been used in FTD with different rates of success. Further research should be directed at understanding and developing new diagnostic and therapeutic modalities to improve the patients' prognosis and quality of life. BioMed Central 2007-06-12 /pmc/articles/PMC1906781/ /pubmed/17565679 http://dx.doi.org/10.1186/1744-859X-6-15 Text en Copyright © 2007 Weder et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Weder, Natalie D
Aziz, Rehan
Wilkins, Kirsten
Tampi, Rajesh R
Frontotemporal Dementias: A Review
title Frontotemporal Dementias: A Review
title_full Frontotemporal Dementias: A Review
title_fullStr Frontotemporal Dementias: A Review
title_full_unstemmed Frontotemporal Dementias: A Review
title_short Frontotemporal Dementias: A Review
title_sort frontotemporal dementias: a review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1906781/
https://www.ncbi.nlm.nih.gov/pubmed/17565679
http://dx.doi.org/10.1186/1744-859X-6-15
work_keys_str_mv AT wedernatalied frontotemporaldementiasareview
AT azizrehan frontotemporaldementiasareview
AT wilkinskirsten frontotemporaldementiasareview
AT tampirajeshr frontotemporaldementiasareview